Ibrance rejected for health insurance benefits

Published: 2017-06-13 09:59:59

Updated: 2017-06-13 09:59:59

The registration of Ibrance Cap(Pfizer Pharmaceuticals Korea), a breast cancer treatment, for the health insurance benefits fell through.

The Health Insurance Benefit Evaluation Committee conducted an health insurance benefit evaluation on 6 products of 5 companies on the 8^th and decided the health insurance benefits on 5 of the products.

The evaluated products were Prolia Prefilled Syringe(o...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.